Orexo将在欧洲过敏与临床免疫学会（EAACI）大会上展示 OX640的临床数据-动脉网

Orexo to present clinical data for OX640 at the EAACI Congress

CISION 等信源发布 2025-06-02 21:11



可切换为仅中文







OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technology

OX640是一种基于粉末形式肾上腺素的鼻腔急救药物，用于治疗严重过敏反应（包括过敏性休克），并基于专有的AmorphOX®技术。

EAACI is a leading global association devoted to allergic and immunology diseases

EAACI 是一个致力于过敏和免疫疾病研究的全球领先协会。

Orexo´s advisor Dr. Anne K Ellis, Professor and Chair of the Division of Allergy & Immunology at Queen's University,

奥雷克斯公司的顾问安妮·K·埃利斯博士，皇后大学过敏与免疫学系教授兼主任，

Ontario, CA

安大略省，加拿大

, will present data from the OX640-002 clinical study.

，将提供来自OX640-002临床研究的数据。

UPPSALA, Sweden

乌普萨拉，瑞典

，

June 2, 2025

2025年6月2日

/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX:

ORXOY

), announces the company will attend the 2025 EAACI Congress in

），宣布公司将参加2025年EAACI大会在

Glasgow, UK

英国格拉斯哥

, on

，打开

June 13-16

6月13日至16日

. The European Academy of Allergy and Clinical Immunology (EAACI) is a leading global association for the treatment of allergic and immunology diseases, including members representing over 16,000 clinicians, researchers, and health professionals from 125 countries.

欧洲过敏与临床免疫学学会（EAACI）是治疗过敏和免疫疾病领域的全球领先协会，拥有来自125个国家、代表超过16,000名临床医生、研究人员和健康专业人士的成员。

在

June 15

6月15日

, Dr.

，博士。

Anne K. Ellis

安妮·K·埃利斯

, Professor and Chair of the Division of Allergy & Immunology at Queen's University (

，皇后大学过敏与免疫学系教授兼主任（

Kingston, Ontario, Canada

加拿大安大略省金斯顿市

) and advisor to Orexo will present on behalf of the company. Dr.

）并作为Orexo的顾问将代表公司进行演讲。博士

Anne K. Ellis

安妮·K·埃利斯

will present data from the OX640-002 clinical study, which, among other findings, demonstrated that epinephrine was absorbed significantly faster under allergic rhinitis conditions compared to normal conditions. These results support a rapid onset of action, even in patients experiencing airway symptoms..

将呈现来自OX640-002临床研究的数据，其中显示，在过敏性鼻炎条件下，肾上腺素的吸收速度比正常情况下显著加快。这些结果表明，即使在出现呼吸道症状的患者中，药物也能快速起效。

In addition to the oral presentation, Orexo's SVP and Head of R&D, Robert Rönn, will present a scientific poster demonstrating detailed stability data for OX640.

除口头报告外，Orexo公司的高级副总裁兼研发主管罗伯特·罗恩还将展示一张科学海报，详细展示OX640的稳定性数据。

'We look forward to attending this important congress. Thanks to our powder-based drug-delivery technology, AmorphOX®, we are able to present strong data from the second clinical study of OX640, along with a leading stability profile. I am confident that OX640 has the potential to become a convenient, effective, and reliable rescue medication for people at risk of severe allergic reactions,' .

“我们期待参加这次重要的大会。得益于我们的粉末基药物递送技术AmorphOX®，我们能够展示OX640第二项临床研究的有力数据，并呈现领先的稳定性特征。我坚信OX640有潜力成为一种便捷、有效且可靠的急救药物，用于帮助面临严重过敏反应风险的人群。”

said

说

Robert Rönn, SVP and Head of R&D.

罗伯特·罗恩，高级副总裁兼研发主管。

For further information contact:

请联系以获取更多信息：

Nikolaj Sørensen, President and CEO

尼古拉·索伦森，总裁兼首席执行官

Lena Wange

莉娜·王

, IR & Communications Director

，投资者关系与传播总监

+46 (0)18 780 88 00

ir@orexo.com

About Orexo

关于 Orexo

Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs.

奥雷克斯是一家瑞典制药公司，拥有30年经验，利用自主配方技术开发改进型药物，满足重大医疗需求。

On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to

在美国市场，Orexo 为阿片类药物使用障碍患者提供创新的治疗解决方案。针对其他治疗领域的产品由全球领先的合作伙伴开发并商业化。2024 年的总净销售额达到

SEK 590 million

5.9亿瑞典克朗

, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.

，员工人数为110人。Orexo在纳斯达克斯德哥尔摩主板上市，并在美国OTCQX市场以美国存托凭证（ORXOY）形式交易。

For more information on Orexo, visit

欲了解有关Orexo的更多信息，请访问

www.orexo.com

. You can also follow Orexo on X, LinkedIn, and YouTube.

您还可以在X、LinkedIn和YouTube上关注Orexo。

About AmorphOX

关于AmorphOX

Orexo's proprietary drug-delivery platform, AmorphOX, is a powder made up of particles that are built using a unique combination of a drug, carrier materials and, optionally, other ingredients.

奥雷克斯公司专有的药物递送平台AmorphOX是一种粉末，由使用药物、载体材料以及可选的其他成分的独特组合构建的颗粒组成。

The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure. .

这些颗粒呈现为各种成分的无定形复合物，具有出色的化学和物理稳定性，以及快速溶解性。该技术适用于广泛的有效成分，并在多项人体临床研究中得到验证，显示出快速且广泛的药物暴露。

About OX640

关于OX640

OX640 is a nasal epinephrine powder-based product for the acute treatment of severe allergic reactions, including anaphylaxis. The product is based on the proprietary AmorphOX drug-delivery platform providing rapid and extensive systemic drug absorption after nasal administration as well as excellent physical and chemical stability.

OX640是一种用于急性治疗严重过敏反应（包括过敏性休克）的鼻用肾上腺素粉末产品。该产品基于专有的AmorphOX药物递送平台，鼻腔给药后可实现快速且广泛的全身药物吸收，同时具备优异的物理和化学稳定性。

Thanks to its unique properties, OX640 has the potential to provide allergic patients with a needle-free, convenient, and rapidly acting allergy rescue product that also has a long shelf-life and allows for flexible storage, both in hot and cold temperatures..

由于其独特的特性，OX640有潜力为过敏患者提供一种无针、便捷、快速起效的过敏急救产品，同时该产品还具有较长的保质期，并且能够在高温和低温条件下灵活存储。

About the OX640-002 study

关于OX640-002研究

The study was a 4-period cross-over study in 30 otherwise healthy subjects with seasonal allergic rhinitis. The study was conducted during allergy season with no ongoing allergy symptoms in subjects. Epinephrine plasma levels, blood pressure and heart rate were collected after administration of two different doses of OX640 and 0.3 mg intramuscular epinephrine.

这是一项4周期交叉研究，对象为30名患有季节性过敏性鼻炎但其他方面健康的受试者。研究在过敏季节进行，受试者当时没有持续的过敏症状。在给予两种不同剂量的OX640和0.3毫克肌肉注射肾上腺素后，收集了肾上腺素血浆水平、血压和心率数据。

In one treatment period, one of the OX640 doses was administered following nasal administration of allergens, producing acute allergic rhinitis symptoms in the subjects..

在一个治疗周期中，一个OX640剂量是在鼻腔给予过敏原后给药的，这导致受试者出现急性过敏性鼻炎症状。

#EAACI2025 #TogetherForAllergy

#EAACI2025 #携手共创过敏新未来

The information was submitted for publication at

该信息已提交出版

8.00 am CET

上午8:00（欧洲中部时间）

打开

June 2

6月2日

, 2025.

，2025年。